Morningstar Investor users sign in here.

Shane Ponraj

Shane Ponraj

 is a Morningstar equity research analyst.

Market is underestimating ASX pathology shares
Stocks
Market is underestimating ASX pathology shares
Morningstar sees several reasons to expect a stronger recover than market consensus.
ResMed’s impressive earnings
Stocks
ResMed’s impressive earnings
Strong device sales and rebound in margin.
Our view on the Sigma / Chemist Warehouse merger
Video
Our view on the Sigma / Chemist Warehouse merger
Is there an opportunity before the ACCC weighs in? 
This cheap ASX share looks 25% undervalued even after 40% rally
Stocks
This cheap ASX share looks 25% undervalued even after 40% rally
Despite advancing from its October low, the undervalued stock of this narrow-moat company may have more room to run.
The cheapest ASX share in our coverage universe
Stocks
The cheapest ASX share in our coverage universe
We still believe this turnaround play is an attractive opportunity after the CEO resigns amid industry challenges. 
Ansell poised to return to growth
Stocks
Ansell poised to return to growth
Progress in productivity program establishes the foundation for earnings growth. 
Cochlear earnings grow rapidly but are the shares a bargain?
Stocks
Cochlear earnings grow rapidly but are the shares a bargain?
Profit is up and the dividend was increased 29% in the latest earnings release.
CSL trial fails to meet hoped for results
Stocks
CSL trial fails to meet hoped for results
How our analyst views the shares after the clinical trial set-back.
Positive earnings from Morningstar best share idea
Stocks
Positive earnings from Morningstar best share idea
Shares rose after strong earnings report but remain materially undervalued. 
Sigma agrees to acquire Chemist Warehouse
Stocks
Sigma agrees to acquire Chemist Warehouse
Our analyst weighs in on the proposed acquisition and Sigma’s capital raise.
of 2
Viewing 1 to 10 of 14